Hi there everyone.
Welcome to my long overdue second part about my report on Amy Prowl and The Marshall Protocol.
This post ( and it might be the last part to be honest ) is going to focus on Articles that I have found dealing with this subject.
Here is an article from Wikipedia about Trevor Marshall, the driving force behind The Marshall Protocol…
Trevor G. Marshall (b. 1948, Adelaide, South Australia ), is a biomedical researcher. Marshall has advanced both a pathogenesis of and treatment for many chronic inflammatory autoimmune diseases and many cancers [1] [2] . According to Marshall, these diseases are caused by a variety of bacterial forms including L-form bacteria and biofilm bacteria, which persist and grow in number by interfering with the proper functioning of the innate immune response. Marshall has proposed that these diseases can be treated by activating the innate immune response by regular doses of olmesartan medoximil angiotensin II receptor antagonist (being used as a Vitamin D Receptor agonist). [3] [4] Patients also take pulsed low doses of five specified bacteriostatic antibiotics, minimize consumption of dietary sources of Vitamin D, and restrict their exposure to sunlight for several years. A 2009 paper by Perez stated that patients with many chronic conditions, including lupus , rheumatoid arthritis , scleroderma , sarcoidosis , Sjögren’s syndrome , autoimmune thyroid disease, psoriasis , ankylosing spondylitis , Reiter’s syndrome , type I and II diabetes mellitus and uveitis had seen some improvement in some of the symptoms of their various diseases [5] . However, one pair of dermatologists have stated that the ability of this Protocol to treat sarcoidosis is only supported by anecdotal data and that it cannot be recommended to patients. [6]
During 2008, Marshall chaired a session at the International Congress on Autoimmunity in Portugal [7] [8] [9] , and delivered a Keynote at the World Gene Congress in Foshan, China. [10] [11]
Trevor Marshall received his PhD in Electrical Engineering from the University of Western Australia in 1984. [12] He also possesses an undergraduate and a masters (1978) degree in Electrical Engineering. [13]
After a year as a tutor in Papua New Guinea , Marshall joined the staff of the Western Australian Institute of Technology (now Curtin University ) in 1975, where he lectured undergraduate courses on electronic design and production until 1982 [14] . After gaining his Masters by thesis in 1978, Marshall moved to the University of Western Australia , where he commenced his PhD research, studying patients suffering from diabetes and infertility at the Charles Gairdner Hospital.
His research involved the design of portable, battery operated programmable pumps for the delivery of pulsatile[ jargon ] LHRH[ jargon ] for treating cryptorchidism , and both male and female infertility . [15] [16]
In 1982, he moved to California . He continued his PhD thesis research while a Visiting Scientist in the Department of Surgery at the Hospital for Sick Children in Toronto ; This led to his thesis Modelling and simulation in diabetes care and a paper on insulin infuser technologies. [17]
Marshall has worked in technology related fields such as electrical and software engineering. Early notable events include in 1963 becoming the youngest person in Australia at the age of 15 to be issued with an amateur’s radio operator’s license [18] and in 1965 setting an Australian UHF long distance communications record. [19] In 1973, Marshall designed an early version of the electronic synthesizer. [20]
In 1988, he founded and became CEO of YARC Systems, a corporation based in California, which went public in 1996. Throughout its 12-year lifespan, YARC researched, developed and marketed products in the areas of graphics and printing. [21]
YARC developed software in partnership with hardware and software suppliers including Microsoft, Apple, and Hamamatsu, the latter using it for PET imaging. [22] YARC supplied Linotype AG with software drivers used for pre-print graphics. YARC’s 1992 joint development agreement with Pixar [23] resulted in the development of multiprocessing drivers for Pixar’s RenderMan, a graphic 3D rendering application, which was an early example of multiprocessing on the Macintosh platform. [23] In 1993, YARC was awarded the MacUser “Eddy” for the “Best Accelerator Card of 1993.” [24] The YARC-XP, released in 1997, was the first Internet-enabled Print Server. [25] In 2001, YARC became insolvent and was liquidated. [26]
From 1986 to 1999, Marshall was a Contributing Editor for BYTE Magazine. In 1999 he transitioned to writing as a columnist for BYTE.com. [27]
Marshall contracted sarcoidosis in the 1970s. Sarcoidosis is a systemic granulomatous disease, which restricts lung functionality, negatively impacts lymph nodes and other organs, and usually becomes end-stage within one or two decades of diagnosis. [28] [29] At least according to most researchers, sarcoidosis is considered to be a member of a class of diseases with an unclear origin and no curative treatment option. [30] [31] .
Sarcoidosis is treated with immunosuppressive drugs, including the corticosteroids . [32] However, these steroids do not cure the illness and are only capable of bringing about periods of relative remission. [28]
As early as 1974, while teaching in Papua New Guinea , Marshall began to think that there was a connection between his exposure to light and flare-ups of his sarcoidosis symptoms. In the decades that followed, he argued that the Vitamin D synthesis caused by incident radiation was playing a crucial role in driving sarcoidosis.
In 1999, he developed an interest in a class of drugs known as Angiotensin Receptor Blockers (ARBs), specifically the class of Angiotensin II receptor antagonists , after learning that patients with sarcoidosis who are administered these drugs often develop a neurological reaction. He started a sabbatical in early 2001 in order to further investigate this reaction.
Marshall hypothesised that ARBs might produce unexpected symptoms in sarcoidosis patients by directly affecting the immune system. In 2006, he performed a study using mathematical modeling to screen several ARBs for the possibility that they might be able to modulate the nuclear receptors of the immune system. [33]
In 2008, Marshall published a paper exploring how, in his words, “lifelong supplementation of the food chain with vitamin D might well be contributing to the current epidemics of obesity and chronic disease.” [34] This was only an explanatory paper; no proper clinical studies of the Marshall Protocol have been carried out.
Marshall performed more molecular modeling in order to further develop his hypothesis on if vitamin D metabolites could modulate the VDR. These models predicted that 25-hydroxyvitamin D, which has the actions of a steroid , might bind and inactivate the receptor, shutting down the body’s first line of defense against intracellular infection. [35] [36]
In 2001, Marshall read a paper by Nilsson, which reported finding genetic material from Rickettsia helvetica in the granuloma of two deceased sarcoidosis patients. This, along with other papers by Mattman and Wirostko, [37] led him to postulate that intraphagocytic, L-form bacteria could drive the biochemical processes observed in sarcoidosis . [38]
Since then, Marshall has suggested that chronic diseases are driven by other bacterial forms including biofilm bacteria. [4] [35]
Marshall’s 2004 paper argues that people who are sick with “ autoimmune ” diseases possess a correctable defect in innate immunity brought about by a dysregulation of vitamin D , which allows slow-growing, mutated bacteria, known as L-form bacteria as well as biofilm bacteria, to proliferate. He also believes that a range of other chronic inflammatory diseaseswhich he terms “Th1 illnesses”– result from the same bacterial pathogenesis as sarcoidosis. Thus, in every Th1 disease, chronic bacterial forms directly interfere with vitamin D metabolism, causing the release of Th1 cytokines . [35]
Marshall believes that patients with Th1 illness are capable of restoring innate immunity by using the ARB Benicar to activate the VDR, while at the same time avoiding exogenous sources of vitamin Dthe kinds of vitamin D present in various foods and catalyzed by exposure to bright lights and sunlight. Along with the help of pulsed, low-dose antibiotics, the body’s immune system can then destroy L-form bacteria, causing a temporary change in a patient’s immunopathology. [39] He argues that the release of cytokines and endotoxins generated by this reaction cause an increase in past or present Th1 symptoms. These concepts became the fundamental aspects of his treatment plan for Th1 illness, which his colleagues named the ‘Marshall Protocol’.
Cpt. Perez (USPHS, ret.) presented data at the 6th International Congress on Autoimmunity reporting symptom improvement using Marshall’s approach in treating Rheumatoid Arthritis, Hashimoto’s Thyroiditis, Uveitis, Psoriasis, Diabetes, Sjogren’s, Celiac, Lupus (SLE), Ankylosing Spondylitis, IBD, Scleroderma, Multiple Sclerosis, and several other autoimmune conditions [40] .
In several US Patent applications in 2006 [41] [42] Marshall contends that his protocol is a treatment or a method of prevention for a wide range of diseases,including at least 35 different autoimmune diseases including rheumatoid arthritis, multiple sclerosis,Type 1 diabetes and Hashimoto’s Thyroiditis. He also asserted in his patent applications that the treatment is also effective in a range of poorly understood illnesses such as chronic fatigue syndrome and gulf war syndrome, as well as several neurodegenerative diseases including Parkinson’s, Multiple Sclerosis, Autism Spectrum Disorder (ASD), Attention Deficit Disorder (ADD), Attention Deficit Hyperactivity Disorder (ADHD), Schizophrenia, Obsessive Compulsive Disorder (OCD), Dysthymia, Bipolar Disorders, Epilepsy, and Dementia.
In 2004, Trevor Marshall founded the Autoimmunity Research Foundation , a California-based non-profit agency. The directors and members of the Foundation aim to
1. promote the Marshall Pathogenesis to doctors and patients
2. communicate with researchers in the field of autoimmunity and Th1 disease
3. run the MP’s study web sites, marshallprotocol.com and sarcinfo.com
4. gain approval from the U.S. Food and Drug Administration (FDA) for medications used in conjunction with the MP [43]
In March 2006, Marshall was invited by the FDA Center for Drug Evaluation and Review to give a presentation in their “Visiting Professor” lecture series. [44] In 2006, he co-authored a chapter about Vitamin D dysregulation. [45]
Marshall is an Adjunct Professor in the School of Biological Sciences and Biotechnology at Murdoch University . [46] [47]
Marshall’s theories and the efficacy of the Marshall Protocol have not been proven through controlled clinical studies. However, neither have his theories been discounted by experts in the field of immunology. The open acknowledgement of the challenges of immunological research and the willingness to consider alternatives approaches is exemplified in the literature by Doherty and Rosen in their 2008 review [48] of treatments for the immune disorder cutaneous sarcoidosis, that “…virtually every treatment is based on minimal evidence-based data and relies almost exclusively on anecdotal information. Despite universal acceptance as standard care, the aforementioned treatments often result in an incomplete clinical response or unacceptable adverse events. In such situations, more innovative treatment options may be used” and “…the clinical experience with tetracycline derivatives has been mixed. That said, there are compelling reports of therapeutic benefit with both doxycycline and minocycline.” The tetracycline, minocycline is a central part of the Marshall Protocol.
While much of what Marshall recommends directly contradicts a large and growing body of evidence that supports the positive role of vitamin D in the human body, vitamin D supplementation has not been shown to improve autoimmune conditions. “Vitamin D affects the expression of over 1,000 genes, so we should not expect a simplistic cause and effect between vitamin D supplementation and disease. The comprehensive studies are just not showing that supplementary vitamin D makes people healthier.” [49] Others would disagree.
What I took particular interest in here is the areas of research concerning Sarcoidosis, and as some of you are already aware I am already using vitamin D for my case study concerning asthma, and I am just amazed at the fact that I have this disease, and yet something like having been diagnosed with Sarcoid better than twenty years ago now, was not something that set off bells and whistles with that doctor as Sarcoid is termed as a granulomatous disease.
Okay, well this part has run a bit longer than I had expected so I will end this here for now, and I will attempt to get another part to this series done in the near future…but you just might have to sign up for my newsletter to read it. 
Hi there everyone.
Welcome to my long overdue second part about my report on Amy Prowl and The Marshall Protocol.
This post ( and it might be the last part to be honest ) is going to focus on Articles that I have found dealing with this subject.
The first article is actually a PDF document that you can find here concerning this subject, and below is just a small snippet of information from the pdf…
Here is an article from Wikipedia about Trevor Marshall, the driving force behind The Marshall Protocol…
What I took particular interest in here is the areas of research concerning Sarcoidosis, and as some of you are already aware I am already using vitamin D for my case study concerning asthma, and I am just amazed at the fact that I have this disease, and yet something like having been diagnosed with Sarcoid better than twenty years ago now, was not something that set off bells and whistles with that doctor as Sarcoid is termed as a granulomatous disease.
Okay, well this part has run a bit longer than I had expected so I will end this here for now, and I will attempt to get another part to this series done in the near future…but you just might have to sign up for my newsletter to read it.
Lew
One Response to “Part Two Of My Thoughts On The Marshall Protocol: Articles”